Journals / MN Kardiyoloji / 2022 / Cilt: 29 - Sayı: 2

Effect of Anxiety on Blood Pressure in Hypertensive COVID-19 Patients

Hipertansif COVID-19 Hastalarında Anksiyetenin Kan Basıncı Üzerine Etkisi

Pages
66–71
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the management of the COVID‐19 outbreak, psychological support treatment in addition to medical treatment may be beneficial, especially in patients with comorbidities such as hypertension.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hypertension is the most common comorbidity accompanying COVID‐19.
📊
Key Findings & Data:This study aimed to investigate the effect of significant anxiety on blood pressure regulation in hyper‐ tensive patients during the COVID‐19 outbreak.
💡
Conclusion & Impact:In the management of the COVID‐19 outbreak, psychological support treatment in addition to medical treatment may be beneficial, especially in patients with comorbidities such as hypertension.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Hypertension is the most common comorbidity accompanying COVID‐19. In addition, a history of hypertension has been cor‐ related with a poor prognosis. This study aimed to investigate the effect of significant anxiety on blood pressure regulation in hyper‐ tensive patients during the COVID‐19 outbreak. Material and Method: A total of 218 patients with a confirmed diagnosis of COVID‐19 were included in the study. The mean age of the patients was 63±9 years, and 53.2% were female. Patients with a history of uncontrolled hypertension or irregular drug use during hos‐ pitalization were excluded from the study. Anxiety levels of all patients were determined using the Beck Anxiety Scale (cut‐off point ≥10). During the isolated ward follow‐up of the patients, blood pressure values were monitored. Additional antihypertensive drug re‐ quirements were recorded. Results: Anxiety is a prevalent symptom in hypertensive patients followed in isolated wards due to COVID‐19 (39.4%). In addition, anx‐ iety is more common in the female gender (61.6% vs. 47.7%; p = 0.044). The need for additional antihypertensive medication increases approximately twofold in patients with anxiety (15.9% vs. 29.1%; p = 0.020). The length of hospital stay was also meaningfully longer in the group with significant anxiety (6.0 ± 2.9 days vs. 7.1 ± 3.2 days; p = 0.034). However, anxiety did not affect prognostic conditions such as intensive care unit referral and mortality. Conclusion: Anxiety is a common psychological disorder in patients treated for COVID‐19. In addition, anxiety is directly related to blood pressure regulation. In the management of the COVID‐19 outbreak, psychological support treatment in addition to medical treatment may be beneficial, especially in patients with comorbidities such as hypertension.

Özet

Amaç: Hipertansiyon COVID‐19’a en sık eşlik eden komorbiditedir. Ayrıca hipertansiyon öyküsü kötü prognozla ilişkilendirilmiştir. Bu ça‐ lışmada, hipertansiyonu olan COVID‐19 hastalarında anlamlı düzeyde anksiyetenin kan basıncı regülasyonu üzerine etkisini değerlen‐ dirmeyi amaçladık. Gereç ve Yöntem: Çalışmaya COVID‐19 tanısı kesinleşmiş 218 hasta dahil edildi. Hastaların ortalama yaşı 63±9’du ve %53,2’si kadındı. Yatış esnasında kontrolsüz hipertansiyon öyküsü veya düzensiz ilaç kullanımı olan hastalar çalışma dışı bırakıldı. Tüm hastaların anksi‐ yete düzeyleri Beck Anksiyete Ölçeği kullanılarak belirlendi (kesme noktası ≥10). Hastaların izole servis takipleri esnasında kan basıncı değerleri izlendi. İlave antihipertansif ilaç gereksinimleri kaydedildi. Bulgular: Hipertansif COVID‐19 hastalarında izole servislerde takip esnasında anksiyetenin oldukça yaygın bir semptom olduğu göste‐ rilmiştir (%39,4). Ayrıca anksiyete kadın cinsiyette daha sık görülmektedir (%61,6 ve %47,7; p=0,044). Anksiyete bulunan hastalarda ila‐ ve antihipertansif ilaç gereksinimi yaklaşık iki kat artmaktadır (%15,9 ve %29,1; p=0,020). Anksiyete bulunan grupta hastanede yatış sü‐ releri belirgin şekilde daha uzundu (6,0 ± 2,9 gün ve 7,1 ± 3,2 gün; p = 0,034). Ancak anlamlı anksiyete bulunmasının yoğun bakım üni‐ tesine sevk ve mortalite gibi prognostik öneme sahip durumlar üzerine etkisi yoktu. Sonuç: COVID‐19 tedavisi gören hastalarda anksiyete sık görülen psikolojik bir bozukluktur. Ayrıca anksiyete doğrudan kan basıncı re‐ gülasyonu ile ilişkilidir. COVID‐19 salgınının yönetiminde medikal tedavinin yanında psikolojik destek tedavisi özellikle hipertansiyon gi‐ bi komorbiditeleri bulunan hastalarda faydalı olabilir.

🔖

Cite This Article

COŞGUN, M. S. (2022). Effect of Anxiety on Blood Pressure in Hypertensive COVID-19 Patients. MN Kardiyoloji, Cilt: 29 - Sayı: 2, 66–71. https://ajindex.com/articles/581442

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Tort FL. Castells M. Cristina J. A comprehensive analysis of genome composition and codon usage patterns of emerging coronaviruses. Virus Res. 2020;283:197976
  2. Peiris J. Guan Y. Yuen K. Severe acute respiratory synd ­ rome. Nature medicine. 2004;10(Suppl 12): S88­97
  3. Zaki AM. van Boheemen S. Bestebroer TM. Osterhaus ADME. Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Eng J Med. 2012;367(19):1814­20
  4. Naming the coronavirus disease (COVID­19) and the virus that causes it. 2020; Available from: https://www.who.int/ emergencies/diseases/novel­coronavirus­2019/technicalguidance/naming­the­coronavirus­disease­(covid­2019)­ and­the­virus­that­causes­it
  5. Cucinotta D. and Vanelli M. WHO Declares COVID­19 a Pandemic. Acta Biomed. 2020;91(1):157­60
  6. Coronavirus Disease (COVID­19) Dashboard. 2021; Avai ­ lab le from:
  7. Baric RS. Emergence of a Highly Fit SARS­CoV­2 Variant. N Eng J Med. 2020;383(27):2684­6
  8. Zhu N. Zhang D. Wanget W. et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China 2019. N Engl J Med. 2020;382(8):727­33
  9. Mann R. Mann R. Perisetti A. Gajendran M. Gandhi Z. Umapathy C. Hemant Goyal Clinical Characteristics, Diag ­ no sis, and Treatment of Major Coronavirus Outbreaks. Front Med (Lausanne). 2020;7:581521
  10. Bansal M. Cardiovascular disease and COVID­19. Diabetes Metab Syndr. 2020;14(3):247­50
  11. Li B. Yang J. Zhaoet F. et al. Prevalence and impact of cardiovascular meta bo lic diseases on COVID­19 in China. Clin Res Cardiol. 2020;109(5):531­8
  12. Torales J. O’Higgins M. Castaldelli­Maia JM. Ventriglio A. The outbreak of COVID­19 coronavirus and its impact on global mental health. Int J Soc Psychiatry. 2020;66(4):317­ 20
  13. Duan L. and Zhu G. Psychological interventions for people affected by the COVID­19 epidemic. Lancet Psychiatry. 2020;7(4):300­2
  14. Ginty A. Carroll D. Roseboom TJ. Phillips AC. de Rooij SR. Depression and anxiety are associated with a diagnosis of hypertension 5 years later in a cohort of late middle­aged men and women. J Hum Hypertens. 2013;27(3):187­90
  15. COVID­19 (SARS­CoV­2 Infection) Guide. 2020, Republic of Turkey, Ministry of Health, Directorate General of Public Health, Study of Scientific Board
  16. Julian LJ. Measures of anxiety: State­Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale­Anxiety (HAD